How to go about securing the best policy for your insurance in Canada.
Latest News
Ontario Car Insurance Rates Drop Slightly + MORE Jan 22nd
Here at RateSupermaket.ca, we keep you in the loop of different ways to save, whether it be on your mortgage, through investments, or on your car insurance. The Financial Services Commission of Ontario (FSCO) has reported that Ontario car insurance rates have dropped by 0.14 per cent on average.
Ca.... More »
Compare auto insurance in Calgary Mar 13th
If you’re buying a new or used car, SUV or pickup truck to drive the streets of Calgary, you’ll also need to shop for auto insurance—it’s required in Canada.
Alberta drivers pay the second-highest car insurance rates in Canada (after Ontario), according to the Automobile Insurance R.... More »
ObamaCare's Hotel California Sep 4th
Democrats work to ban an affordable health insurance option..... More »
Statistics Canada reports real GDP up in January 2024 Apr 1st
Canada’s real gross domestic product grew 0.6% in January 2024, helped by the end of public sector strikes in Quebec in November and December, Statistics Canada said Thursday.
What is GDP?
Gross domestic product (GDP) is a statistic economists use to measure the total amount of goods and se.... More »
Canada’s best travel credit cards 2022 + MORE Jan 7th
With a good travel credit card in your name, going on a trip can suddenly become more affordable (when you are ready to travel again, of course). And, you can get even more value if you sign up for the right travel credit card—one that doesn’t just focus on points, but also has perks such as lou.... More »
Novartis wins US OK for biosimilar version of Amgen’s Enbrel
– canadianbusiness.com
U.S. regulators have approved the first near-copy of Enbrel, drugmaker Amgen’s pricey biologic medicine for treating rheumatoid arthritis and other immune system disorders.
The follow-up version of Enbrel, dubbed Erelzi, was developed by Swiss drug giant Novartis, which would not disclose the planned list price for Erelzi.
Novartis also couldn’t say when the new medicine will be launched by its Sandoz unit, which makes generic drugs and “biosimilars” — nearly identical versions of biologic drugs produced in living cells.
Erelzi is the third biosimilar drug approved by the Food and Drug Administration. It’s also the second approved biosimilar developed by Novartis, and the second that will compete with an Amgen drug.
Enbrel was first approved in 1998. It can cost about $4,000 per month without insurance.
The post Novartis wins US OK for biosimilar version of Amgen’s Enbrel appeared first on Canadian Business – Your Source For Business News.
The follow-up version of Enbrel, dubbed Erelzi, was developed by Swiss drug giant Novartis, which would not disclose the planned list price for Erelzi.
Novartis also couldn’t say when the new medicine will be launched by its Sandoz unit, which makes generic drugs and “biosimilars” — nearly identical versions of biologic drugs produced in living cells.
Erelzi is the third biosimilar drug approved by the Food and Drug Administration. It’s also the second approved biosimilar developed by Novartis, and the second that will compete with an Amgen drug.
Enbrel was first approved in 1998. It can cost about $4,000 per month without insurance.
The post Novartis wins US OK for biosimilar version of Amgen’s Enbrel appeared first on Canadian Business – Your Source For Business News.
